Physician profile
Sam Farhad Daneshvari
NPI 1851496145
$6,105.84
in general payments reported to CMS, 2019-2025
32 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $525 · 2021: $972 · 2022: $592 · 2023: $1,040 · 2024: $1,177 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.13 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,296.26 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $782.77 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $567.34 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $411.80 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $400.39 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $344.01 | 2019-2024 | Auryxia, Vafseo |
| Glaxosmithkline, LLC. | $280.90 | 2021-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $267.23 | 2021-2025 | |
| Vifor Pharma, INC. | $227.74 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $160.97 | 2019-2023 | Velphoro, Korsuva |
| Nuwellis, INC. | $157.71 | 2021-2022 | |
| Travere Therapeutics, INC. | $142.85 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $138.57 | 2019-2021 | |
| Horizon Therapeutics Plc | $132.19 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $120.63 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $118.54 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Opko Pharmaceuticals, LLC | $109.95 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.03 | 2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.45 | 2024-2025 | Jardiance |
| Abbvie INC. | $50.16 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $44.93 | 2019 | |
| Alexion Pharmaceuticals, INC. | $36.01 | 2019 | |
| Genzyme Corporation | $28.20 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.37 | 2023 | Xifaxan |
| Ani Pharmaceuticals, INC. | $22.60 | 2023 | Purified Cortrophin Gel |
| Allergan, INC. | $18.95 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.34 | 2021 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
| Amarin Pharma, INC. | $12.35 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Daneshvari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.